Got Questions? Send us a message! We explore whether two old antiparasitics, fenbendazole and ivermectin, can meaningfully impact cancer by disrupting cell structure, metabolism, and immune signaling while challenging how drugs get approved and funded. We lay out the science, question the incentives, and call for trials that prioritize survival and quality of life. • Fenbendazole as a microtubule destabilizer leading to cell‑cycle arrest and apoptosis • Potential to bypass efflux pump resist...
All content for Fenben® Voices is the property of Fenbendazole Help and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Got Questions? Send us a message! We explore whether two old antiparasitics, fenbendazole and ivermectin, can meaningfully impact cancer by disrupting cell structure, metabolism, and immune signaling while challenging how drugs get approved and funded. We lay out the science, question the incentives, and call for trials that prioritize survival and quality of life. • Fenbendazole as a microtubule destabilizer leading to cell‑cycle arrest and apoptosis • Potential to bypass efflux pump resist...
S2EP2 Fenbendazole’s Double Life: How a Dewormer Sparked Serious Cancer Research
Fenben® Voices
15 minutes
3 weeks ago
S2EP2 Fenbendazole’s Double Life: How a Dewormer Sparked Serious Cancer Research
Got Questions? Send us a message! We trace fenbendazole’s unlikely path from dewormer to a serious subject in oncology, clarifying how microtubules and p53 shape the scientific interest and where the evidence genuinely stands. We share practical guardrails on sourcing, clinical partnership, and mindset while separating early promise from proof. • selective toxicity explains parasite targeting while sparing mammals • microtubule disruption leads to mitotic arrest and apoptosis • p53 stabiliza...
Fenben® Voices
Got Questions? Send us a message! We explore whether two old antiparasitics, fenbendazole and ivermectin, can meaningfully impact cancer by disrupting cell structure, metabolism, and immune signaling while challenging how drugs get approved and funded. We lay out the science, question the incentives, and call for trials that prioritize survival and quality of life. • Fenbendazole as a microtubule destabilizer leading to cell‑cycle arrest and apoptosis • Potential to bypass efflux pump resist...
